newsfilter
← Latest News
Business Wire·

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company's Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Re